Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (3131)	6/1/1999 2:36:00 PM
From: Art Vandelay AIA	Read Replies (1) \| Respond to of 10280

To be clear on the Maris dispute, this is what happened: Last summer, Maris downgraded when SEPR got into the 70s based on points that were, at a minimum, disputable. His biggest point was that SEPR had gotten ahead of itself. BTW, he had only been covering the stock for a couple months, and his original price target (when the stock was in the mid 40s) was in the 50s, so it wasn't illogical that he'd downgrade on the runup. Many were angry at the downgrade (SEPR included), as it was closely correlated with a pullback from the 70s back to the 50s. Personally, I find it odd that the pullback would be blamed on what one analyst said amongst many, but those who had paper losses were screaming for his head. There was a conference call soon thereafter, and SEPR IP mistakenly sent him his fax late, so he was not on the call. It was an oversight, and it happened once, though many have speculated that there is a sinister Sepracorian plot which involves Dr. Evil and his bald cat against a certain Mr. Maris. I'm not sure if Maris ever upgraded, but his opinions have recently been as negative as ever and again coincided with this most recent decline. Good luck all longs! By the way, I concur with the idea that the market is way undervaluing Zyrtec, but that just means that smart money is buying.

To: Biomaven who wrote (3131)	6/2/1999 1:10:00 PM
From: Don Miller	Respond to of 10280

Peter, Richard, anybody with contacts DenverSouth70, on YC thinks a drug IMS report will tell how Xopenex sales are going. Can anybody help? He posted #738: While these antecodotal stories are interesting and somewhat valuable, it would be much more valuable if someone could get the IMS data on this drug. Any of the major brokerage houses with serious coverage of SEPR will be watching for real sales data. Can anyone help here?